Patients with TNBC were, for example, less frequently diagnosed with a tumour size of ≥5 cm (8% versus 34%) or node-positive disease (33% versus 100%) when compared with patients with high-risk HR+/HER2− BC. This evidence concerns the gene HR and breast cancer.